The role of complement activation in autoimmune liver disease

Maaike Biewenga, Arantza Farina Sarasqueta, Maarten E. Tushuizen, Eveline S. M. de Jonge-Muller, Bart van Hoek, Leendert A. Trouw

Research output: Contribution to journalReview articleAcademicpeer-review

20 Citations (Scopus)

Abstract

Introduction: The complement system, an essential part of the innate immune system, is involved in various autoimmune diseases. Activation of the complement system by autoantibodies results in immune activation and tissue damage. At the moment little is known about the role of the complement system in autoimmune liver disease, including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Since inhibition of the complement system is currently being tested in several autoimmune diseases as a therapeutic option, its role in autoimmune liver disease requires further clarification. Methods: A review of the literature was performed on studies investigating complement activation in PBC, PSC and AIH. Since data on AIH were lacking immunohistochemical staining for IgG, C1q, C3d, C4d and C5b9 was performed on liver tissue of nine AIH patients, two healthy controls and one positive control (acute liver failure caused by paracetamol intoxication). Results: Immunohistochemical analysis in AIH revealed increased production of C3 and C4 by hepatocytes. Despite a strong staining for IgG in the immune infiltrate in AIH, C3d, C4d and C5b9 deposition was only present in one AIH patient and the deposition was restricted to the interface between portal tracts and liver parenchyma. No deposition was found in all other AIH patients or healthy controls. Literature review showed raised plasma C3 and C4 levels in AIH, PBC and PSC patients compared to healthy controls. For PBC and PSC no complement depositions at the bile ducts were reported. Conclusion and discussion: Although complement is involved in various autoimmune diseases, the role of complement in autoimmune liver disease seems limited. Therefore it is unlikely that complement inhibition will become a novel treatment option for these diseases.
Original languageEnglish
Article number102534
JournalAutoimmunity Reviews
Volume19
Issue number6
Early online date2020
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Autoimmune hepatitis
  • Complement activation
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis

Cite this